Eli Lilly and Company is bringing its renowned Gateway Labs model to Philadelphia, opening a new 44,000-square-foot site at 2300 Market in the city’s Center City life sciences hub. 

 

The facility, developed by Breakthrough Properties, will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies.

 

“Philadelphia has long led biotech innovation—from pioneering vaccines to breakthrough gene and CAR-T therapies,” said Julie Gilmore, Ph.D., vice president and global head of Lilly Gateway Labs. “Early-stage companies need more than lab space—they need experienced partners to guide discoveries from concept to clinic.”

 

The move highlights Lilly’s strategy of placing Gateway Labs in cities where research excellence meets entrepreneurial ambition. With Philadelphia joining Boston, South San Francisco, and San Diego, Lilly now operates four U.S. innovation hubs designed to accelerate the translation of foundational research into clinical breakthroughs.

 

Part of Lilly Catalyze360, Gateway Labs provides startups with lab infrastructure, strategic guidance, and access to capital and advanced R&D tools, including AI-driven models. Since opening in 2019, Gateway Labs companies have raised over $3 billion, advancing more than 50 therapeutic programs.

 

Philadelphia’s new site is expected to strengthen the city’s life sciences ecosystem, fostering collaboration among biotechs, venture partners, and academic institutions while driving the next generation of medical innovation.